GLP-1 Shortage Explained: Why Medications Are Hard to Find

Introduction

The GLP-1 supply chain story is a case study in pharmaceutical capacity, FDA shortage rules, and what happens when demand for a class of drugs explodes 10x in three years.

The shortage that defined 2022-2024 has officially ended on FDA paperwork. The reality on the ground in pharmacies is more complicated, and the compounded sterile injectable market that grew up around the shortage isn’t going away quietly.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Why Did GLP-1 Medications Go Into Shortage?

Demand outran manufacturing capacity by a wide margin. Semaglutide and tirzepatide are complex peptide molecules that require specialized fermentation, purification, and sterile fill-finish lines. Building those lines takes 3-5 years.

Quick Answer: FDA declared tirzepatide shortage resolved October 2024, semaglutide shortage resolved February 2025

When Wegovy® launched in 2021, Novo Nordisk projected modest demand for an obesity indication. The actual demand exceeded forecasts by an estimated 5-10x by 2023. Eli Lilly’s Mounjaro® launch in 2022 hit the same wall.

The FDA placed semaglutide and tirzepatide on the official drug shortage list in 2022 and 2023 respectively. That listing triggered specific rules around compounded versions under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

When Did the FDA Officially End the Shortage?

The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025. Both decisions were challenged in court by compounding industry groups but were ultimately upheld.

The shortage resolution had immediate regulatory consequences. 503B outsourcing facilities, which could produce compounded versions during the shortage, lost that authority. 503A pharmacies, which compound for individual patient prescriptions, retained narrow exceptions for specific clinical needs.

Patients who relied on compounded semaglutide or tirzepatide during the shortage had to either return to brand-name therapy, find a 503A pharmacy producing customized formulations, or transition to alternative agents.

What Is the Difference Between 503A and 503B Compounding?

A 503A pharmacy compounds medications for individual patients based on specific prescriptions. They’re regulated by state boards of pharmacy and the FDA. Production volume is limited, and shipments must be tied to patient names.

A 503B outsourcing facility produces compounded drugs in bulk, often without patient-specific prescriptions, and is regulated to higher cGMP standards similar to traditional manufacturers. 503B facilities require FDA registration and inspection.

During the shortage, 503B facilities supplied large volumes of compounded GLP-1s to telehealth platforms. After the shortage ended, that pathway closed. 503A pharmacies can still produce GLP-1 formulations for specific clinical reasons, like dose customization, B12 co-formulation, or excipient allergies.

Can You Still Get Compounded Semaglutide in 2026?

Yes, through licensed 503A pharmacies producing formulations with clinically valid customization. The FDA’s narrow exception allows compounding when a commercial product isn’t clinically suitable for a specific patient.

Examples include patients who need doses not commercially available (like 1.5 mg, between Wegovy’s 1 mg and 1.7 mg steps), patients with allergies to commercial excipients (phenol, metacresol), or patients needing B12 co-formulation.

TrimRx works with 503A partner pharmacies that produce customized compounded formulations for patients with documented clinical needs. The personalized treatment plan model fits the 503A framework when prescriptions are individualized.

How Much Manufacturing Capacity Have Novo and Lilly Added?

Both companies have spent unprecedented sums expanding production. Eli Lilly committed $23 billion in capital expenditure from 2020-2025, including new facilities in Indiana, North Carolina, Ireland, and Germany.

Novo Nordisk acquired Catalent’s fill-finish facilities for $16.5 billion in 2024, adding three plants in Italy, Belgium, and Indiana. Novo’s parent foundation also financed new active pharmaceutical ingredient (API) sites in Denmark.

By late 2025, combined capacity for semaglutide and tirzepatide was estimated to support 20-30 million patients globally per year, up from roughly 3-5 million in 2022.

Why Are Some Pharmacies Still Out of Stock?

Shortage resolution at the FDA level doesn’t mean every pharmacy has every dose in stock every day. Distribution is uneven across regions, payer networks, and dose strengths.

The 1.7 mg and 2.4 mg Wegovy doses tend to be more reliably stocked than the lower titration doses. Mounjaro and Zepbound® supply has been more consistent than Ozempic® and Wegovy at the highest doses.

Local pharmacy out-of-stock situations usually resolve within 1-2 weeks. Patients waiting more than that should call alternate pharmacies or ask their prescriber about substitutions.

Key Takeaway: Compounded GLP-1 sales peaked at an estimated $1-2 billion in 2024 before the shortage ended

How Does the Compounded Market Work Now?

The post-shortage compounded GLP-1 market is smaller and more clinically focused than the 2023-2024 boom. Producers are licensed 503A pharmacies producing customized formulations under individual prescriptions.

Pricing has stabilized between $200-400 per month for compounded semaglutide, depending on dose and pharmacy. That’s still substantially below the $1,000-1,300 retail of Wegovy and Mounjaro.

Quality varies. Patients should verify their compounded medication comes from a state-licensed pharmacy with documented USP <797> sterile compounding compliance. TrimRx publishes the pharmacy partners and their licensure status as part of the assessment quiz flow.

What’s the Difference Between Wegovy, Ozempic, and Compounded Semaglutide?

Wegovy and Ozempic are FDA-approved brand-name semaglutide injectables produced by Novo Nordisk. Wegovy is approved for obesity at doses up to 2.4 mg weekly. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly.

Compounded semaglutide is produced by licensed pharmacies using the same active ingredient. Excipients may differ (some compounds use B12, niacinamide, or different preservatives), and concentrations may be customized.

Efficacy data exists for brand-name semaglutide through trials like STEP 1 (Wilding 2021 NEJM, 14.9% weight loss at 68 weeks). Compounded formulations don’t have equivalent trial data, though they use the same active molecule.

Is the GLP-1 Shortage Really Over?

For FDA shortage list purposes, yes. For patient access, mostly. Brand-name supply has improved dramatically. Pricing remains a barrier, with monthly costs of $1,000-1,300 for Wegovy and Mounjaro without insurance.

Compounded versions remain available through 503A pharmacies for clinically appropriate patients. The market has consolidated around fewer, larger compounding pharmacies with documented quality systems.

For someone exploring options in 2026, the main questions are insurance coverage (most plans still don’t cover obesity GLP-1s), cost, and whether a clinically valid case for compounding exists.

What’s the Future of GLP-1 Supply?

Capacity will continue expanding through 2027-2028 as Lilly and Novo bring new facilities online. Oral semaglutide (Rybelsus®) and other oral GLP-1 candidates may shift some demand away from injectables.

Generic semaglutide is expected after 2031 when the original patent expires, with biosimilar competition likely to drop prices substantially. India has already approved generic semaglutide manufacturing in anticipation.

For TrimRx patients, the supply picture is stable for now. The clinical and pricing considerations are now the primary decisions, not whether the medication will be available.

Bottom line: 503B outsourcing facilities lost shortage exception status in 2025 and must restrict production

FAQ

Why Is Wegovy Still Hard to Find at My Pharmacy?

FDA shortage resolution is national, but local distribution varies. Call multiple pharmacies in your area, or ask your prescriber about substituting Zepbound, which has had more reliable supply through 2025-2026.

Can I Still Get Compounded Semaglutide Legally?

Yes, through licensed 503A pharmacies producing customized formulations under individual prescriptions for specific clinical reasons. Mass-produced 503B compounded GLP-1 is no longer legal after February 2025.

Why Are Compounded Versions So Much Cheaper Than Brand-name?

Compounded versions don’t carry the brand-name R&D, marketing, and patent cost markup. The active ingredient itself is relatively inexpensive to produce. The price gap reflects pricing models, not necessarily quality differences in active drug.

Will Ozempic or Wegovy Go Generic Soon?

Not until 2031 at the earliest, when the original semaglutide patent expires. Tirzepatide patents extend further. Biosimilar competition may arrive sooner in markets like India, China, and Brazil.

Is Compounded Semaglutide as Effective as Wegovy?

The active molecule is the same. Compounded versions lack their own clinical trial data, so direct equivalence claims aren’t permitted. Anecdotal and pharmacokinetic data suggest similar effect when properly compounded.

What Should I Look for When Buying Compounded GLP-1?

Verify the pharmacy is state-licensed, USP <797> compliant, and operating under a valid prescription. Avoid websites selling “research only” or “not for human use” peptides, which are unregulated and unsafe.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.